Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: partial US clinical hold for evobrutinib; Takeda pulls back early AAV gene therapy and rare hematology research; Lilly and Novo shape up for obesity battle; Vir’s new CEO talks to Scrip; and the declining state of pain R&D.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 14 April 2023, including: partial US clinical hold for evobrutinib; Takeda Pharmaceutical Co. Ltd. pulls back early AAV gene therapy and rare hematology research; Eli Lilly and Company and Novo Nordisk A/S shape up for obesity battle; Vir Biotechnology, Inc.’s new CEO talks to Scrip; and the declining state of pain R&D.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Takeda Halts Early R&D Efforts In AAV Gene Therapies And Rare Hematology" - Scrip, 12 Apr, 2023.)
(Also see "Lilly And Novo Nordisk Shape Up For Obesity Treatment Battle Of The Heavyweights" - Scrip, 6 Apr, 2023.)
(Also see "Big Year Ahead For New Vir CEO De Backer" - Scrip, 11 Apr, 2023.)
(Also see "Pain Therapy R&D Innovation, Investment Declining, BIO Reports" - Scrip, 7 Apr, 2023.)